• 1
    Kaufmann M,Hortobagyi GN,Goldhirsch A, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J Clin Oncol. 2006; 24: 19401949.
  • 2
    Bonadonna G,Valagussa P,Brambilla C, et al. Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute. J Clin Oncol. 1998; 16: 93100.
  • 3
    Fisher B,Bryant J,Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. 1998; 16: 26722685.
  • 4
    Scholl SM,Fourquet A,Asselain B, et al. Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6. Eur J Cancer. 1994; 30A: 645652.
  • 5
    Semiglazov VF,Topuzov EE,Bavli JL, et al. Primary (neoadjuvant) chemotherapy and radiotherapy compared with primary radiotherapy alone in stage IIb-IIIa breast cancer. Ann Oncol. 1994; 5: 591595.
  • 6
    Smith IC,Heys SD,Hutcheon AW, et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol. 2002; 20: 14561466.
  • 7
    Wolmark N,Wang J,Mamounas E,Bryant J,Fisher B. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr. 2001; 30: 96102.
  • 8
    Mauri D,Pavlidis N,Ioannidis JP. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst. 2005; 97: 188194.
  • 9
    Bear HD,Anderson S,Smith RE, et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2006; 24: 20192027.
  • 10
    Colleoni M,Gelber S,Coates AS, et al. Influence of endocrine-related factors on response to perioperative chemotherapy for patients with node-negative breast cancer. JClin Oncol. 2001; 19: 41414149.
  • 11
    Gianni L,Baselga J,Eiermann W,Guillem Porta V,Semiglazov V,Garcia-Conde J. First report of the European Cooperative Trial in operable breast cancer (ECTO): effects of primary systemic therapy (PST) on local-regional disease [abstract]. Proc Am Soc Clin Oncol. 2002; 21:Abstract 132.
  • 12
    Gianni L,Baselga J,Eiermann W, et al. Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy. Clin Cancer Res. 2005; 11(24 pt 1): 87158721.
  • 13
    Bhatnagar A,Batzl C,BHausler A,Schieweck K,Lang M,Trunet P. Pharmacology of non-steroidal aromatase inhibitors. In: PasqualiniJ, KatzenellenbogenB, eds. Hormone-dependent cancer. New York: Marcel Dekker; 1996: 155168.
  • 14
    Cameron DA,Anderson ED,Levack P, et al. Primary systemic therapy for operable breast cancer--10-year survival data after chemotherapy and hormone therapy. Br J Cancer. 1997; 76: 10991105.
  • 15
    Gazet JC,Ford HT,Coombes RC, et al. Prospective randomized trial of tamoxifen vs surgery in elderly patients with breast cancer. Eur J Surg Oncol. 1994; 20: 207214.
  • 16
    Eiermann W,Paepke D,Appfelstaedt J, et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter trial. Ann Oncol. 2001; 12: 15271532.
  • 17
    Mauriac L,Debled M,Durand M, et al. Neoadjuvant tamoxifen for hormone-sensitive non-metastatic breast carcinomas in early postmenopausal women. Ann Oncol. 2002; 13: 293298.
  • 18
    Makris A,Powles TJ,Ashley SE, et al. A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer. Ann Oncol. 1998; 9: 11791184.
  • 19
    Robertson JF,Ellis IO,Elston CW,Blamey RW. Mastectomy or tamoxifen as initial therapy for operable breast cancer in elderly patients: 5-year follow-up. Eur J Cancer. 1992; 28A(4–5): 908910.
  • 20
    Kaufmann M,von Minckwitz G,Rody A. Preoperative (neoadjuvant) systemic treatment of breast cancer. Breast. 2005; 14: 576581.
  • 21
    Ellis MJ,Coop A,Singh B, et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol. 2001; 19: 38083816.
  • 22
    Common terminology criteria for adverse events v3.0 (CTCAE). National Cancer Institute. March 31, 2003. Available at: (accessed March 17, 2007).
  • 23
    Fleiss J. The Design and Analysis of Clinical Experiments. New York: John Wiley; 1986.
  • 24
    Abrial C,Mouret-Reynier MA,Cure H, et al. Neoadjuvant endocrine therapy in breast cancer. Breast. 2006; 15: 919.
  • 25
    Castiglione-Gertsh M. Adjuvant endocrine therapies for postmenopausal women: standards and not [abstract]. Breast. 2005; 14( suppl 1): S9. Abstract S24.
  • 26
    Coombes RC,Hall E,Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med. 2004; 350: 10811092.
  • 27
    Dixon JM,Bundred N. Aromatase inhibitors for early breast cancer therapy: a choice of effective treatment strategies. Eur J Surg Oncol. 2006; 32: 123125.
  • 28
    Winer EP,Hudis C,Burstein HJ, et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol. 2005; 23: 619629.
  • 29
    Bonadonna G. From adjuvant to neo-adjuvant chemotherapy in high-risk breast cancer: the experience of the Milan Cancer Institute. Steiner Award Lecture 1992. Int J Cancer. 1993; 55: 14.
  • 30
    Schwartz GF,Birchansky CA,Komarnicky LT, et al. Induction chemotherapy followed by breast conservation for locally advanced carcinoma of the breast. Cancer. 1994; 73: 362369.
  • 31
    Semiglazov V,Ivanov V,Ziltzova E. Neoadjuvant endocrine therapy of postmenopausal breast cancer patients. Paper presented at: 14th International Congress on Anti-Cancer Treatment; February 1–4, 2003; Paris, France.
  • 32
    Semiglazov V,Kletsel A,Semiglazov V, et al. Exemestane (E) vs tamoxifen (T) as neoadjuvant endocrine therapy for postmenopausal women with ER+ breast cancer (T2N1–2, T3N0–1, T4N0M0) [abstract]. J Clin Oncol. 2005 ASCO Annual Meeting Proceedings [Post-Meeting Edition]. 2005; 23(16S): 530.
  • 33
    Dixon J,Anderson T,Miller W. Phase IIb study of neoadjuvant exemestane (EXE) in locally advanced breast cancer [abstract]. Proc Am Soc Clin Oncol. 2001; 20. Abstract 1908.
  • 34
    Gil M,Barnadas A,Cirera L, et al. Exemestane as neoadjuvant treatment in patients > 65 years with T > 3cm; preliminary results of a multicenter Spanish phase II trial [abstract]. Paper presented at: San Antonio Breast Cancer Symposium; December 11–14, 2002; San Antonio, Tex.
  • 35
    Krainick U,Astner A,Jonat W,Wallwiener D. Phase II study to define safety and efficacy of exemestane as preoperative therapy for postmenopausal patients with primary breast cancer-final results of the German Neoadjuvant Aromasin Initiative (GENARI) [abstract]. Breast Cancer Res Treat. 2003; 82: S55.
  • 36
    Lichtenegger W,Hackl W,Huettner C, et al. Exemestane combined with weekly docetaxel as preoperative treatment for breast cancer [abstract]. Proc Am Soc Clin Oncol. 2001; 20. Abstract 1832.
  • 37
    Wolf C,Hackl W,Kuemper S,Schewe T,Eiermann W. Exemestane combined with epirubicin, Q1w X (8–12), as preoperative chemoendocrine treatment for patients with primary breast cancer: a phase I study [abstract]. Proc Am Soc Clin Oncol. 2001; 20:Abstract 1819.
  • 38
    Tubiana-Hulin M,Spyratos F,Becette V, et al. Phase II study of neo-adjuvant exemestane in postmenopausal patients with operable breast cancer [abstract]. Breast Cancer Res Treat. 2003; 82: S106.
  • 39
    Therasse P,Arbuck SG,Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92: 205216.
  • 40
    Chevallier B,Roche H,Olivier JP,Chollet P,Hurteloup P. Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate. Am J Clin Oncol. 1993; 16: 223228.
  • 41
    Dombernowsky P,Smith I,Falkson G, et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol. 1998; 16: 453461.
  • 42
    Dixon JM,Jackson J,Renshaw L,Miller WR. Neoadjuvant tamoxifen and aromatase inhibitors: comparisons and clinical outcomes. J Steroid Biochem Mol Biol. 2003; 86: 295299.
  • 43
    Goss P. Endocrine treatment beyond 5 years [abstract]. Breast. 2005; 14( suppl 1): S3.
  • 44
    Mouridsen H,Gershanovich M,Sun Y, et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol. 2003; 21: 21012109.
  • 45
    Paridaens R,Dirix L,Lohrisch C, et al. Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer. Ann Oncol. 2003; 14: 13911398.
  • 46
    Paridaens R,Therasse P,Dirix L, et al. First line hormonal treatment (HT) for metastatic breast cancer (MBC) with exemestane (E) or tamoxifen (T) in postmenopausal patients (pts): a randomized phase III trial of the EORTC Breast Group. J Clin Oncol. 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 22, No 14S (July 15 Supplement), 2004: 515.
  • 47
    Baum M,Buzdar A,Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer. 2003; 98: 18021810.
  • 48
    Coates AS,Keshaviah A,Thurlimann B, et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1–98. J Clin Oncol. 2007; 25: 486492.
  • 49
    Goss PE,Ingle JN,Martino S, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst. 2005; 97: 12621271.
  • 50
    Jakesz R,Jonat W,Gnant M, et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet. 2005; 366: 455462.
  • 51
    Goldhirsch A,Glick JH,Gelber RD,Coates AS,Thurlimann B,Senn HJ. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol. 2005; 16: 15691583.